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between susceptibility genes and a diverse group of environmental factors. The GSTP1 Ile105Val
polymorphism has been associated with asthma in several studies.
Objective: To examine the hypothesis that polymorphism in the GSTP1 locus is associated with
asthma and related phenotypes in a population of subjects stratiﬁed by airway obstruction as well
as atopic status (IgE level and history).
Methods: Fifty patients with bronchial asthma and ﬁfty normal control subjects were enrolled in
this study and were subjected to asthma questionnaire, spirometric studies, conventional polymer-
ase chain reaction (PCR) with enzyme digestion to determine GSTP1 genotype, serum immuno-
globulin E (IgE) measurement and eosinophilic count.volume at the end of the ﬁrst
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106 M.I. Mahmoud et al.Results: The genotype distributions for GSTP1 gene polymorphism in bronchial asthma subjects
and controls showed no signiﬁcant difference. Both patients and controls were found to be in
Hardy-Weinberg equilibrium. Presence of the Val/Val genotype did not confer a decreased risk
for developing bronchial asthma (odd ratio (OR) = 0.34, 95% conﬁdence interval (CI) = 0.06–
1.91, P= 0.0331). There was no signiﬁcant relationship between GSTP1 genotypes and the severity
of asthma. In addition, the frequency of GSTP1 genotypes distribution achieved no signiﬁcance
when assessed according to degree of airway obstruction or control of asthma. No associations
between the GSTP1 genotypes and atopic status or IgE level were identiﬁed.
Conclusion: The present study does not support a substantial role of GSTP1 gene polymorphism in
the development of asthma. However, large studies with accurate measurement of the environmen-
tal exposure are needed in order to reach adequate power to detect gene-environment interactions
and other genes involved in the antioxidant pathway.
ª 2011 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Bronchial asthma is a complex chronic inﬂammatory disorder
of the airways characterized by reversible airﬂow obstruction,
airway hyperresponsiveness, and activation of inﬂammatory
cells and mediators in the airways. It is a complex multifacto-
rial disease with airway oxidative stress being a cardinal fea-
ture and an important pathway in asthma pathogenesis.1–3
Advances in asthma management are likely to depend on a
better understanding of how genetic factors inﬂuence suscep-
tibility to, outcome in3,4 and pharmacogenomics5 of this
disease.
Although asthma is polygenic, present knowledge suggests
that candidate genes include those that determine the key clin-
ical phenotypes of bronchial hyperresponsiveness and atopy.
Bronchial hyperresponsiveness could be considered as an exag-
gerated response to bronchoconstrictor stimuli. It reﬂects the
presence of bronchial inﬂammation and usually its severity
parallels that of asthma symptoms, although some individuals
with bronchial hyperresponsiveness remain asymptomatic.6
While host atopy is a recognized risk factor for airway
inﬂammation, atopy alone cannot cause asthma.6 Indeed,
although 30–50% of the population is atopic, only 5–7% will
develop asthma.1
The presence of inﬂammation in the airway is an important
biochemical feature of asthma. Oxidative stress, with the for-
mation of reactive oxygen species (ROS), is a key component
of inﬂammation.1,7 Although host antioxidant defenses should
detoxify ROS, individuals differ in their ability to deal with an
oxidant burden, and such differences are in part genetically
determined.7 Inability to detoxify reactive oxygen species
should perpetuate the inﬂammatory process, activate broncho-
constrictor mechanisms, and precipitate asthma symptoms.
Glutathione-S-transferase (GST) enzymes, which play an
important role in antioxidant defenses, may therefore inﬂuence
asthma risk. GST are recognized as a supergene family of
enzymes critical in cell protection from the toxic products of
reactive oxygen species (ROS)-mediated reactions, and modu-
lation of eicosanoid synthesis.6
Many candidate genes are implicated in the pathogenesis of
bronchial asthma.8–10 Glutathione S-transferase (GST) is such
a gene due to its role in protection against oxidative stress.11
The GST enzyme (E.C.2.5.1.18) superfamily consists of alpha,
kappa, mu, omega, pi, sigma, theta, and zeta isoforms in hu-
mans;11 enzymes encoded by members of the mu, theta, andpi class GST gene families are critical in the protection of cells
from reactive oxygen species.7,12 GSTP1 – the predominant
GST expressed in human lung – is a candidate because it cat-
alyzes the detoxiﬁcation of byproducts of lipid and DNA oxi-
dation.13,14 Genetic polymorphisms in GSTP1 have been
implicated as risk factors for asthma. Four alleles of this gene
have been identiﬁed: GSTP1*A (Ile105-Ala114), GSTP1*B
(Val105-Ala114), GSTP1*C (Val105-Val114), and GSTP1*D
(Ile105-Val114).14,15
A common polymorphism results in a substitution of valine
(Val) for isoleucine (Ile) at codon 105, which forms part of the ac-
tive site for binding of hydrophobic electrophiles, and affects sub-
strate-speciﬁc catalytic activity. Homozygotes for the Val allele
have been shown to be at reduced risk of asthma in some studies.16
In this context our aim was to study the genetic polymor-
phisms in GSTP1 in Egyptian patients suffering from bron-
chial asthma and comparing them with control subjects. We
have examined the hypothesis that polymorphism in the
GSTP1 locus is associated with asthma and related pheno-
types. We have determined the prevalence of these genotypes
in a population of subjects stratiﬁed by atopic status (IgE level
and history) as well as by airway obstruction.2. Methods
This case-control study included ﬁfty patients with bronchial
asthma and ﬁfty normal subjects as control for the genotyping.
All subjects were lifelong nonsmokers and had not suffered a
viral infection within at least the 6 weeks preceding the study.
The study protocol was approved by the local ethics commit-
tee, and all subjects provided written informed consent.
All Patients with bronchial asthma were selected according
to GINA guidelines.17 The questionnaire, used in the present
study, was derived from the Asthma Therapy Assessment Ques-
tionnaire (ATAQ),18 asthma-related quality-of-life score,19 and
the Asthma Control Questionnaire (ACQ).202.1. Spirometric study
Spirometric measurements were made by using Chestgraph
HI-701 (version 1).
The ATS/ERS standards21,22 were followed for spirometric
measurements and reversibility test. The standards for choos-
ing FEV1, VC, FEV1/VC and reversibility are:
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(2) FEV1 is referred to VC rather than just FVC. Ratio of
FEV1 to VC is capable of accurately identifying more
obstructive patterns than its ratio to FVC, because
FVC is more dependent on ﬂow.The patients were either asthmatic and atopic or asthmatic
but nonatopic. Individuals were diagnosed as nonatopic on
the basis of having no past history of allergic symptoms and
normal IgE levels. Atopic individuals were deﬁned by: (1) a per-
sonal history of allergies, seasonal rhinitis, eczema, or allergic
conjunctivitis and (2) total serum IgE level > 100 IU/ml. Pa-
tients were diagnosed as having asthma by: (1) a history of
wheezing, cough, dyspnea, and/or chest tightness; (2) spiromet-
ric demonstration of airﬂow obstruction reversible with a
b-agonist bronchodilator.21 Patients were classiﬁed into mild,
moderate and severe, and controlled and uncontrolled accord-
ing to GINA guidelines.17 Subjects with any other past or
current disorder, respiratory or nonrespiratory, were excluded.2.2. Genotyping for Ile105Val GSTP1 polymorphism2
Genomic DNA was extracted from blood lymphocytes using
Wizard Genomic DNA puriﬁcation kit (Promega) by alcohol
precipitation method and following instructions of the
manufacturer.
The GSTP1 c.313Aﬁ G resulting in Ile105Val polymor-
phism was determined using PCR based restriction fragment
length polymorphism described by Harries et al.23 The oligo-
nucleotides used to amplify the target DNA of a 176 bp frag-Figure 1 Captured gel image of GSTP1genotype polymorphism
using Aw261 RFLP. The PCR and digested products were
resolved in 3% agaorse gel stained with ethidium bromide and
visualized using UV transilluminator. Lane 1: DNA marker, Lane
2: Undigested PCR product (176 bp), Lane 3: Val/Val genotype
(homozygous digestion by Aw261 resulting in 85 and 91 bp
bands), Lanes 4 and 6: Ile/Val genotype (heterozygous digestion
by Aw261 resulting in 176 bp band of wild allele and 85 and 91 bp
bands of variant allele), Lane 5: (Ile/Ile) wild genotype and
absence of digestion by Aw261 restriction endonuclease.ment are as follows F: ACCCCAGGGCTCTATGGGAA
and R: TGAGGGCACAAGAAGCCCCT. Genomic DNA
(100 ng) was used as a DNA template in a total of 50 ll reac-
tion containing 1· PCR master mix of master mix GoTaq
Master Mix (Promega, Inc, Madison, USA) and 25 picomoles
of each primer. The reaction condition was as follows: initial
denaturation step at 97 C for 5 min followed by 35 repetitive
cycles of denaturation at 94 C for 30 s, annealing at 55 C for
60 s and extension at 72 C for 60 s. Final extension at 72 C
for 5 min was also included. The PCR products were digested
in 25 ll for 1 h at 37 C with 2U Alw261 (Fermentas, Life Sci-
ence, EU). The digested products were then resolved in 3%
agarose gel stained with ethidium bromide. The presence of
a-176 pb fragment indicated the wild-type genotype (Ile/Ile),
whereas the 85 and 91 pb fragments indicated the homozygous
polymorphic genotype (Val/Val). Heterozygote was recorded
in presence of all three fragments as shown in Fig 1. Negative
and positive controls were included in all reactions.
2.3. Serum IgE estimation
IgE was analyzed by nephelometery, in which polysterene par-
ticles coated with monoclonal antibodies to IGE are aggre-
gated when mixed with sample containing human IgE.
Method standardization was performed against the IFCC/
PCR/CAP reference preparation. The samples were automati-
cally diluted 1:20 to obtain a measuring range from 25.0 to
975.8 IU/mL. Reference interval in adults is <100 IU/mL.24
2.4. Eosinophilic count
Total and absolute eosinophil count were estimated using auto-
mated count on Sysmex counter and Romanowsky stain.25
2.5. Statistical analysis
The raw data were coded and transformed into coding sheets.
The results were checked. Then, the data were entered into
SPSS system ﬁles (SPSS package version 18) using personal
computer. Output drafts were checked against the revised
coded data for typing and spelling mistakes. Finally, analysis
and interpretation of data were conducted.
The following statistical measures were used:
 Descriptive statistics including frequency, distribution,
mean, and standard deviation were used to describe differ-
ent characteristics.
 Kolmogorov–Smirnov test was used to examine the nor-
mality of data distribution.
 Univariate analyses including: t-test, ANOVA test, and
Kruskal Wallis test were used to test the signiﬁcance of
results of quantitative variables. Moreover, Pearson Chi-
Square test were used to test for signiﬁcance among qualita-
tive variables.
 Genotypes frequency of GSTP1 gene polymorphism in
bronchial asthma subjects were tested for being expressed
in Hardy-Weinberg equilibrium using Chi-Square test.
 Odds ratio and 95% conﬁdence interval were calculated to
estimate risk causedbyGSTP1gene polymorphismanddiffer-
ent studied parameters among cases with bronchial ashma.
 The signiﬁcance of the results was at the 5% level of
signiﬁcance.
Table 1 The personal characteristics of the studied cases and controls.
Personal characteristics Cases (n= 50) Controls (n= 10) Signiﬁcance (P)
Sex
Males 28% 50% 0.172
Females 72% 50%
Age (years)
Range 18–63 19–63 0.573
Mean ± SD 38.4 ± 12 40.8 ± 14.4
BMI (kg/m2)
Range 17.0–50.2 17.9–37.9 0.770
Mean ± SD 28.8 ± 6.7 29.5 ± 6.6
X2: Pearson chi-square test.
Table 2 The laboratory and pulmonary function results among studied cases and controls.
Laboratory/pulmonary function results Cases (n= 50) Controls (n= 10) Signiﬁcance (P)
WBC count/ml (·1000)
Min–Max 4.5–9.7 4.7–8.4 t= 0.46 (0.65)
Mean ± SD 6.8 ± 1.4 6.6 ± 1.3
Esinophils count/ml
Min–Max 135–840 130–694 t= 0.234 (0.023)*
Mean ± SD 448.2 ± 170.5 311.5 ± 159.9
Esinophils%
Min–Max 3–10 2–9 t= 2.61 (0.012)*
Mean ± SD 6.5 ± 1.9 4.7 ± 2.0
FEV1 (L)
Min–Max 0.6–4.4 2.1–4.7 t= 2.18 (0.033)*
Mean ± SD 2.8 ± 0.9 2.9 ± 0.9
FEV1%
Min–Max 27.6–116.9 88.8–102.9 t= 7.024 (<0.0001)*
Mean ± SD 71.5 ± 20.4 93.5 ± 3.9
FVC (L)
Min–Max 1.4–5.7 2.6–5.6 t= 0.94 (0.351)
Mean ± SD 3.5 ± 1.1 3.9 ± 1.0
SVC (L)
Min–Max 1.4–5.7 2.6–5.6 t= 0.842 (0.403)
Mean ± SD 3.6 ± 1.1 3.9 ± 1.0
FEV1/SVC
Min–Max 37.3–81.4 71.1–83.7 t= 6.538 (<0.0001)*
Mean ± SD 61.5 ± 14.2 77.6 ± 4.4
* Signiﬁcant at P= 0.05.
Table 3 Distribution of GSTP1 Genotypes among patients with bronchial asthma and control subjects.
GSTP1 genotypes Cases (n= 50) Control (n= 50) P Odds ratio (95%CI)
Ile/Ile 22 (44.0%) 15 (30.0%) X2 = 2.62 (0.269)
Val/Val 3 (6.0%) 6 (12.0%) 0.34 (0.06–1.91)
Ile/Va 25 (50.0%) 29 (58.0%) 0.59 (0.23–1.49)
ORs were calculated against Ile/Ile.
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The personal characteristics of the studied cases and controls
are summarized in Table 1. The cases and controls were
matched as regards age, sex and body mass index (BMI).Table 2 shows the laboratory and pulmonary function
results among studied cases and controls.
Eosinophilic count and percent, FEV1, FEV1% pre-
dicted, and FEV1/SVC showed a statistically signiﬁcant dif-
ference between cases and controls whereas FVC and SVC
Table 4 Distribution of GSTP1 Allele frequencies among patients with bronchial asthma and control subjects.
No. GSTP1 genotypes Allele frequencies
Ile/Ile Val/Val Ile/Val Ile Val
Cases 50 22 (44.0%) 3 (6.0%) 25 (50.0%) 0.69 0.31
Controls 50 15 (30.0%) 6 (12.0%) 29 (58.0%) 0.59 0.41
X2 = 2.17, P= 0.141.
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patients with bronchial asthma into ordered categories as
regards airway dysfunction. First, patients with mild asthma
(17 patients = 34%) to be compared with those with moder-
ate and severe asthma (33 patients = 66%) (Table 6).
Second, those having FEV1P 80% predicted (16 pa-Table 5 Laboratory and pulmonary function results of the studied
Laboratory/pulmonary function results GSTP1 genotype
Ile/Ile (n= 22) V
WBCs count/ml (·1000)
Min–Max 4.5–9.65 4
Mean ± SD 7.4 ± 1.5 5
Esinophils count/ml
Min–Max 135–840 2
Mean ± SD 482.4 ± 170.9 5
Esinophils%
Min–Max 3–9 6
Mean ± SD 6.5 ± 1.8 8
Ig E (IU/ml)
Min–Max 16.4–3070 2
Mean ± SD 672.1 ± 896.3 3
FEV1 (L)
Min–Max 0.92–4.43 1
Mean ± SD 2.4 ± 1.0 1
FEV1%
Min–Max 43.3–115.1 4
Mean ± SD 76.2 ± 22.3 6
FVC (L)
Min–Max 1.8–5.7 3
Mean ± SD 3.7 ± 1.3 3
SVC (L)
Min–Max 1.88–5.71 3
Mean ± SD 3.7 ± 1.3 3
FEV1/SVC
Min–Max 43.2–81.4 4
Mean ± SD 63.5 ± 10.9 5
Change of FEV1 (L)
Min–Max 0.02–0.73 0
Mean ± SD 0.32 ± 0.2 0
Change of FEV1%
Min–Max 0.01–34.1 1
Mean ± SD 15.6 ± 9.6 2
Change of FVC%
Min–Max 0.02–17.6 2
Mean ± SD 6.8 ± 5.8 7
KX2: Kruskal Wallis test.tients = 32%) and those with FEV1 < 80% predicted (34
patients = 68%) (Table 7). Third, as regards control of
asthma, we classiﬁed the patients into patients with
controlled (10 patients = 20%), partially controlled (5 pa-
tients = 10%) and uncontrolled (35 patients = 70%) asthma
(Table 8).cases according to GSTP1 genotypes.
Signiﬁcance (P)
al/Val (n= 3) Ile/Val (n= 25)
.8–6.7 4.6–9.3 KX2 = 5.75 (0.056)
.9 ± 0.9 6.5 ± 1.4
83–643 139–749 KX2 = 2.199 (0.333)
14.7 ± 201.0 410.0 ± 165.2
–10 3–9 KX2 = 3.26 (0.196)
.7 ± 2.3 6.2 ± 1.9
62–375 16.4–4250 KX2 = 0.187 (0.911)
29.7 ± 59.7 848.2 ± 1279.2
.4–2.3 0.62–4.12 KX2 = 0.934 (0.627)
.9 ± 0.5 2.2 ± 0.9
5.9–75.7 27.6–116.9 KX2 = 2.03 (0.362)
2.1 ± 15.1 68.4 ± 18.8
.0–3.5 1.4–5.4 KX2 = 1.209 (0.546)
.3 ± 0.3 3.4 ± 1.0
.0–3.6 1.4–5.4 KX2 = 0.904 (0.636)
.3 ± 0.3 3.4 ± 1.0
5.7–67.4 37.3–77.9 KX2 = 0.925 (0.630)
7.1 ± 10.8 62.8 ± 12.0
.39–0.41 0.07–0.57 KX2 = 2.651 (0.266)
.4 ± 0.01 0.3 ± 0.1
7.6–28.1 0.02–36.5 KX2 = 2.641 (0.267)
1.8 ± 5.5 14.9 ± 9.5
.3–14.6 0–44.8 KX2 = 0.604 (0.739)
.3 ± 6.4 6.9 ± 9.1
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Using Alw261 restriction enzyme analysis for the GSTP1 poly-
morphism three genotypes were found: Ile/Ile, Ile/Val, and
Val/Val. Samples showing a band of 176 bp band are homozy-
gous for the Ile allele (restriction site absent), samples revealing
85 and 91 pb fragments bp bands are homozygous for the Val
allele (restriction site present) and samples showing all three
fragments are heterozygous (Tables 3 and 4, Fig. 1).
3.2. Genotype distributions for GSTP1 gene polymorphism in
bronchial asthma subjects and controls (Table 3 and 4)
The genotype distributions for GSTP1 gene polymorphism in
bronchial asthma subjects and controls showed no signiﬁcant
difference (P= 0.269) where the homozygous Ile/Ile genotype
was present in 22 cases (44%) and 15 of the control group
(30%),the Val/Val genotype was observed in only 3 cases
(6%) and 6 of the control group (12%), while the heterozygous
Ile/Val was found in 50% of cases (25 subjects) and 58% of theTable 6 Association of GSTP1 genotypes with degree of severity o
GSTP1 genotypes Cases
Mild asthma Moderate/severe asthma
Ile/Ile 10 (58.8%) 12 (36.4%)
Val/Val 0 (0.0%) 3 (9.1%)
Ile/Val 7 (41.2%) 18 (54.5%)
P1: signiﬁcance between mild and moderate/severe asthma.
P2: signiﬁcance between cases and controls.
Table 7 Association of GSTP1 genotypes with degree of airway ob
GSTP1 genotypes FEV1% less than 80 FEV1% 80 or
Ile/Ile 12 (36.4%) 10 (58.8%)
Val/Val 3 (9.1%) 0 (0.0%)
Ile/Val 18 (54.5%) 7 (41.2%)
NA: cannot be calculated.
Table 8 Association of GSTP1 genotypes with age of onset, level o
Medical history GSTP1 genotype
Ile/Ile (n= 22) V
No. % N
Age of onset of asthma
Childhood 12 54.5 3
Adulthood 10 45.5 0
Control of disease
Uncontrolled 14 63.6 3
Partially controlled 2 9.1 0
Controlled 6 27.3 0
Severity of asthma
Mild 10 45.5 0
Moderate 4 18.1 2
Severe 8 36.4 1controls (29 subjects) (Table 3). The allele frequencies of the
Val and Ile alleles in asthmatic patients (Table 4) were 0.31
and 0.69 respectively whereas in controls we reported frequen-
cies of 0.41 and 0.59 for Val and Ile alleles respectively with no
signiﬁcant difference between both groups (P= 0.141). Both
patients and controls were found to be in Hardy–Weinberg
equilibrium (P= 0.233 and 0.159 respectively). Presence of
the Val/Val genotype did not confer a decreased risk for devel-
oping bronchial asthma (OR= 0.34, 95% CI = 0.06–1.91,
P= 0.0331). Moreover, no association was found between
GSTP1 gene polymorphism and degree of asthma severity
(P= 0.269) (Table 6).
Table 5 shows laboratory and pulmonary function tests
results of the studied patients with bronchial asthma accord-
ing to GSTP1 genotyping. There were no signiﬁcant differ-
ences between patients with different GSTP1 genotypes as
regards WBCs count, eosinophilic count, eosinophilic per-
centage and IgE levels. Also there were no signiﬁcant differ-
ences between patients with different GSTP1 genotypes as
regards variables related to the degree of airway obstructionf asthma.
Control P1 P2
15 (30.0%) X2 = 3.23 (0.198) X2 = 2.62 (0.269)
6 (12.0%)
29 (58.0%)
struction.
more P Odds ratio (95%CI)
X2 = 3.23 (P= 0.198) 1.0
NA
2.14 (0.55–8.62)
f control and degree of severity of asthma.
al/Val (n= 3) Ile/Val (n= 25)
o. % No. %
100.0 11 44.0
0.0 14 56.0
100.0 18 72.0
0.0 3 12.0
0.0 4 16.0
0.0 7 28.0
66.7 11 44.0
33.3 7 28.0
Table 10 Atopic history of the studied patients with bronchial asthma according to GSTP1 genotyping.
Variables GSTP1 genotype Signiﬁcance (P)
Ile/Ile (n= 22) Val/Val (n= 3) Ile/Val (n= 25)
No. % No. % No. %
History of atopy
Absent 13 59.1 1 33.3 15 60.0 X2 = 0.88 (0.67)
Present 9 40.9 2 66.7 10 40.0
Signiﬁcance: chi-square test.
Table 9 IgE level according to Genotype distributions for GSTP1 gene polymorphism in patients with bronchial asthma.
GSTP1 genotypes Ig E P Odds ratio (95%CI)
Less than 100 More than 100
Ile/Ile 7 (31.8%) 15 (68.2%) X2 = 1.90 (0.386) 1.0
Val/Val 0 (0.0%) 3 (100.0%) 0.0 (0.0–6.6)
Ile/Val 5 (20.0%) 20 (80.0%) 0.54 (0.12–2.41)
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predicted, FEV1/SVC, change of absolute FEV1 and
FEV1% of predicted after administration of inhaled
bronchodilator.3.3. Association of GSTP1 genotypes with severity of airway
obstruction
The frequencies of GSTP1genotypes in the studied patients
with bronchial asthma achieved Hardy–Weinberg equilib-
rium. We stratiﬁed the ﬁfty patients with bronchial asthma
into ordered categories as regards airway dysfunction. First,
patients with mild asthma (17 patients = 34%) to be com-
pared with those with moderate and severe asthma (33 pa-
tients = 66%) (Table 6). Second, those having
FEV1P 80% predicted (16 patients = 32%) and those with
FEV1 < 80% predicted (34 patients = 68%) (Table 7).
Third, as regards control of asthma, we classiﬁed the patients
into patients with controlled (10 patients = 20%), partially
controlled (5 patients = 10%) and uncontrolled (35 pa-
tients = 70%) asthma (Table 8). The data were inspected
according to the stratiﬁcation to determine whether GSTP1
genotypes were associated with severity of airway dysfunc-
tion. Table 6 shows the GSTP1 genotype frequencies accord-
ing to the severity of asthma. Chi - square test analysis
showed absence of signiﬁcant relationship between GSTP1
genotypes and the severity of Asthma. In addition, the fre-
quency of GSTP1 genotypes distribution achieved no signiﬁ-
cance when assessed according to degree of airway
obstruction or control of asthma (Tables 7 and 8). The rela-
tive frequencies of the GSTP1 Ile105 and GSTP1 Val105 al-
leles in the groups stratiﬁed by severity of airway obstruction
were not found to be signiﬁcantly different.
3.4. Association of GSTP1 genotypes with atopy
As regards atopy we repeated stratiﬁcation of patients: First,
those with IgE < 100 (12 patients = 24% patients) and those
with IgE > 100 (38 patients = 76%). Second, those withhistory of atopy (21 patients = 42%) and those without his-
tory of atopy (29 patients = 58%). Table 9 shows GSTP1
genotype frequencies in relation to IgE level. Frequencies for
GSTP1 genotypes in subjects with IgE levels < 100 IU/ml
and >100 IU/ml were not signiﬁcantly different (P= 0.44).
Table 10 shows association of GSTP1 genotypes with atopic
history. No associations between the GSTP1 genotypes and
atopic status were identiﬁed.4. Discussion
Asthma is a complex multifactorial disease with an obvious ge-
netic predisposition, immunological aberration, and involve-
ment of environmental factors. Polymorphisms of the GST
genes are known risk factors for some environmentally-related
diseases. Several population studies have linked genetic varia-
tion in human GSTP1 with enhanced susceptibility to asthma
and the severity of symptoms.26–28
In 2000 Fryer et al.14 identiﬁed associations between
GSTP1 genotype and both bronchial hyperresponsiveness
and atopy. Ile105/Val105 genotype was linked with a signiﬁ-
cantly reduced risk of airway reactivity/obstruction that was
intermediate to that with the GSTP1 Ile105/Ile105 and GSTP1
Val105/Val105 genotypes. They suggested that GST genes are
candidates for having a role in bronchial hyperresponsiveness
because the enzymes they encode modulate ROS levels.29 Fryer
et al.14 hypothesized that individual ability to detoxify ROS
and their products, determined by polymorphism in genes such
as those for GST, contributes to the development of bronchial
hyperresponsiveness and asthma. They reported that the pres-
ence of GSTP1Val/Val genotype conferred a sixfold lower risk
of asthma than did GSTP1Ile/Ile and that the frequency of
GSTP1Val/Val genotype correlated negatively with severity
of airway dysfunction.
In 2001 Hemmingsen et al.13 suggested that GSTP1 (Val
105- Ala 113) and possibly GSTP1 (Val105-Val114) are protec-
tive against asthma and related phenotypes.
In 2000 Spiteri et al.6 reported that the association between
the GSTP1 genotype and severity of airway dysfunction
112 M.I. Mahmoud et al.remained signiﬁcant after correction for potential confounding
factors (age, sex, skin prick tests, and IgE levels). They sug-
gested that GSTP1 genotypes have potential implications for
individual susceptibility to the damaging effects of ROS.
In 2004 Aynacioglu et al.27 have also reported that the fre-
quency of GSTP1 Val homozygote was signiﬁcantly lower in
the group of patients with asthma than in the control individ-
uals (3.8% versus 12.1%, P = .01).
In 2006 Romieu et al.16 found that asthmatic children with
glutathione S-transferase P1 Valine/Valine genotypes appear
more susceptible to developing respiratory symptoms related
to ozone exposure.
In 2007 Hanene et al.30 in their works on Tunisian children,
suggested the presence of associations of GSTM1, T1, and P1
with childhood asthma and atopy. As for the GSTP1, they
found signiﬁcant differences between cases and control regard-
ing the genotype frequencies of the GSTP1Ile105Val polymor-
phisms. They found that asthmatic children have low
frequency of GSTP1Val allele compared with healthy children
(P = .002).
In 2008 Imboden et al.31 suggested that GSTP1 Ile105Val
genotype strongly determines the progression of BHR to phy-
sician-diagnosed asthma in the general population.
In 2009 Babusikova11 suggested that increased oxidative
stress and GST-T1 genetic polymorphism are associated with
children asthma and atopy and, therefore, may contribute to
the pathogenesis of asthma.
In 2010 Piacentini et al.2 studied the gene-environment
interactions in a multicentre Italian ﬁeld study and reported
that GSTA1, GSTM1, GSTO2 and GSTT1 genotypes found
in the group of asthmatic patients seem to differ from the fre-
quencies of those found in the control group.
In 2008 Jiansheng Zhou et al.32 performing their work in
Mouse Model of Asthma demonstrated that the ability of
GSTP1 to attenuate allergic responses directly correlated with
the levels of GSTP1 expression in the mouse lung. They
deﬁned GSTP1 as an important modulator of allergic airways
disease.
In the present study, the homozygous genotype (Ile/Ile) was
present in 44% of the patients and in 30% of the controls, the
Val/Val genotype was observed in only 6% of patients and
12% of controls while the heterozygous genotype Ile/Val was
found in 50% of patients and 58% of controls with no signif-
icant difference between both groups (P= 0.331) (Table 1).
The present study took place between 2007 and 2011. In
2010 Minelli et al.8 performed their meta-analysis using a total
of 14 published and 3 primary studies with 3363 affected and
14 442 non-affected. Although these studies suggested a possi-
ble protective effect of the Val allele, but heterogeneity was
extreme. Few studies of them evaluated wheezing and BHR
and most reported no associations, although weak evidence
was found for positive associations of GSTM1 null and
GSTP1 Val allele with wheezing and a negative association
of GSTP1 Val allele with BHR. Minelli et al.8 ﬁndings did
not support a substantial role of GST genes alone in the
development of asthma.
Mak et al.33 investigated the association of GST gene poly-
morphisms and its enzyme activity with the risk of asthma in
Hong Kong Chinese adults. They reported that the distribu-
tion of various genotypes or alleles of the GSTT1, GSTM1
and GSTP1 was not signiﬁcantly different between patients
with asthma and healthy controls.Presence of the Val/Val genotype in our study did not con-
fer a decreased risk for developing bronchial asthma
(OR= 0.34, 95% CI = 0.06–1.91, P= 0.0331); also, no asso-
ciation was found between GSTP1 gene polymorphism and
degree of asthma severity. Minelli et al.8 also reported a non
signiﬁcant risk in his Meta-analyses on GSTP1 Ile105Val poly-
morphism in a total of 14 published and 3 primary studies with
3363 affected and 14 442 non-affected individuals, where OR
equaled 0.79 (CI = 0.57–1.08) for Val/Val vs Ile/Ile.8
Several studies were not in agreement with our results sug-
gesting that subjects with the GSTP1 Val/Val genotype have
reduced risk of asthma compared to Ile/Ile subjects.6,16,34–36
Romieu et al.16 also stated that children with GSTP1 Ile/Ile
genotype were more likely to have moderate-to-severe asthma
(P= 0.009) than children with GSTP1 Ile/Val or Val/Val
genotypes.
Many factors could account for the observed discrepancies
among studies with the racial and environmental differences
among the populations being highly signiﬁcant contributors.
Piacentini et al.2 analyzed the possible association between
polymorphism in several cytosolic GST genes including
GSTP1, air pollution and asthma development. Among all
the polymorphisms studied, the frequencies of GSTA1,
GSTM1, GSTO2 and GSTT1 genotypes but not GSTP1
genotypes found in the group of asthmatic patients seem to
differ from the frequencies of those found in the control
group. They concluded that the ﬁnal result of their research
should hopefully lead to a better understanding of gene-envi-
ronment interactions, so allowing earlier prediction and diag-
nosis of asthma disease and providing an efﬁcient means of
prevention.
In the present study both patients and controls were found
to be in Hardy Weinberg equilibrium (P= 0.233 and 0.159
respectively). This was in agreement with Fryer et al.14 who
reported that allele frequencies achieved Hardy–Weinberg
equilibrium. The Hardy–Weinberg equilibrium states that both
allele and genotype frequencies in a population remain constant
– that is, they are in equilibrium – from generation to genera-
tion unless speciﬁc disturbing inﬂuences are introduced. Those
disturbing inﬂuences include non-random mating, mutations,
selection, limited population size, ‘‘overlapping generations’’,
random genetic drift, gene ﬂow andmeiotic drive. Genetic equi-
librium is an ideal state that provides a baseline against which
to measure change.37
4.1. Association of GST genotypes with atopy
In the present study atopy and eosinophilia were signiﬁcantly
associated with asthma.
Asthma and allergy represent complex phenotypes. Strong
evidence for genomic factors predisposing subjects to asth-
ma/allergy is available. However, methods to utilize this infor-
mation to identify high risk groups are variable.38
We stratiﬁed our patients into asthmatic and atopic (42%),
and asthmatic but not atopic (58%). We did not identify signif-
icant associations between GSTP1 and atopy in our study pop-
ulation. Also, in our study there was no signiﬁcant difference
in subjects carrying different GSTP1 genotypes as regards lev-
els of IgE (whether > or <100 IU/ml) P= 0.44. The sample
size of ﬁfty patients with asthma limited our power to detect
statistically signiﬁcant associations. This is not in agreement
with Fryer et al.14 who reported that subjects with IgE levels
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Val105/Val105 frequencies as compared with those with IgE
levels <100 IU/ml.
In contrary to our ﬁndings, Tamer et al.36 found that sub-
jects with the GSTP1 homozygous Val/Val genotype had a
3.55 fold increased risk of having atopic asthma compared to
nonatopic asthma (OR= 3.55; 95% CI, 1.10–12.56). These
results suggested that the GSTT1 and GSTM1 null genotypes
and the GSTP1 Val/Val polymorphism may play important
roles in asthma pathogenesis. It is possible that intermediate
electrophilic metabolites, arising in the ﬁrst phase of detoxiﬁ-
cation, are not metabolized by GST enzymes in asthmatic
patients and are not excreted. These intermediate metabolites
may damage cells and generate oxidative stress, and so con-
tribute to the pathogenesis of asthma.36
A variety of review papers describe genes associated with
allergy/asthma.38–41 Ober et al.40 list genes associated with
asthma or atopy in more than 10 studies. Joubert et al.9 sug-
gested that GSTP1’s role in xenobiotic metabolism and antiox-
idation is consistent with asthma etiology. They suggested that
variation in this gene may result in differing metabolism of
environmental toxins across individuals. They speculated that
individuals with multiple risk alleles across GSTP1 genes are
more susceptible to harmful effects of environmental toxins,
and that this sensitivity may contribute to the development
of asthma or asthma exacerbation.
Spiteri et al.6 showed that the frequency of the GSTP1 Val/
Val genotype was reduced in atopic subjects compared with
nonatopic control. They hypothesized that susceptibility to
persistent airway inﬂammation in atopic individuals is charac-
terized by an inherited deﬁciency in the effectiveness of detox-
iﬁcation of inhaled irritants and products of oxidative stress
such as reactive oxygen species (ROS).
4.2. Eiosinophilic count
In the present study there were statistically signiﬁcant differ-
ence between asthmatic patients and control as regards eosin-
ophilic count and eosinophilic percentage. However there was
no association between them and GSTP1.
An imbalance between the oxidative forces and the antiox-
idant defense systems favoring an oxidative injury has been
implicated in the pathogenesis of asthma.42 Oxidative injury
leads to increased lipid peroxidation, increased airway reactiv-
ity and secretions, production of chemoattractant molecules,
and increased vascular permeability,7,43 which collectively lead
to an augmentation of the existing inﬂammation that is a hall-
mark of asthma. There is ample evidence supporting the pres-
ence of a systemic oxidative injury in asthma. An increased
production of reactive oxygen species was shown for eosino-
phils and macrophages obtained from the peripheral blood
of patients with asthma.44,45
It was found that the increased oxidative burden in asthma
was the result both of increased oxidative stress as evidenced
by increased malondialdehyde; and of decreased antioxidant
capacity as evidenced by the lowered reduced glutathione.46
GSTP1 works by catalyzing the detoxiﬁcation of base prope-
nals that arise from DNA oxidation forming reduced glutathi-
one i.e. it is responsible for the antioxidant defense system.29
This may explain absence of correlation between eosinophilic
count and GSTP1 as each of them works on the different limb
of the oxidants/antioxidant system.4.3. Association of GSTP1 with airway obstruction and severity
of asthma
In the present study, as expected, there were signiﬁcant differ-
ences in FEV1 values between the asthmatic and control
groups. We examined the relationship between GSTP1 geno-
types and ordered categories representing various methods to
classify airway dysfunction. Patients with mild asthma were
compared to those with moderate and severe asthma. Also we
repeated stratiﬁcation of patients into two groups: those having
FEV1P 80% predicted and those with FEV1 < 80% pre-
dicted. Finally as regards control of the asthma, we classiﬁed
the patients into patients with controlled, partially controlled
and uncontrolled asthma. We did not ﬁnd any association be-
tween GSTP1 genotypes and either form of degree of airway
dysfunction in asthma.
Although the val105 val genotype of the GSTP1 enzyme was
found to be a signiﬁcant determinant of the oxidative burden in
the systemic circulation,8 Dut et al.3 reported that it had no ef-
fect on the airways. Dut et al.3 examined the variables that had
a potential to inﬂuence the oxidative stress such as age, sex, age
of onset, skin test positivity, IgE levels, eosinophil counts,
smoke exposure, pet ownership, family history of atopic dis-
eases, asthma diagnosis, asthma severity, and polymorphisms
at GSTM1, GSTT1, and GSTP1 genes. They concluded that
the only factor that determines the oxidative stress is the pres-
ence of the airways disease, i.e. asthma. This is consistent with
our ﬁnding as regards absence of correlation between polymor-
phism at GSTP1 gene and airway dysfunction which is related
to oxidative stress and inﬂammation. In this respect, it was
found to be some difference between the systemic circulation
and the airways. Dut et al. used exhaled breath condensate as
a noninvasive method to investigate the oxidative burden in air-
ways. They showed that in addition to the systemic level, there
is a very strong oxidative burden at the local level, i.e., in the
airways of asthmatic children.3 The increased oxidative burden
in the airways has two components: increased oxidative stress
as evidenced by increased malondialdehyde and decreased anti-
oxidant capacity as evidenced by the lowered glutathione.3
Kelly et al. in a study involving 20 asthmatics and 20 controls,
had found that oxidized glutathione content in bronchoalveo-
lar lavage was higher in asthma patients than in controls
whereas reduced glutathione content was similar.47 As reduced
glutathione is the factor that is affected by GSTP1, this explains
absence of GSTP1 polymorphism effect on airway dysfunction.
Any therapeutic approach targeting the oxidative burden in
asthma should deﬁnitely take this into account because abolish-
ing the oxidative insult in both the systemic and local compart-
ments may be necessary to achieve a full therapeutic effect.
In agreement to our ﬁndings, Minelli et al.8 performed a
systematic review and meta-analysis including unpublished
data from the large Avon Longitudinal Study of Parents and
Children (ALSPAC). They reported lack of evidence of an
important role of GST genes in the development of asthma,
wheezing and bronchial hyperresponsiveness which is in agree-
ment with negative ﬁndings on lung function in children for all
three GST genes from the ALSPAC, although an association
between GSTM1 and GSTP1 genes and lung function in child-
hood has been previously suggested.48
In their systematic review, Minelli et al.8 found that few
studies evaluated the effects of GSTP1 on wheezing and bron-
chial hyperresponsiveness, and the ﬁndings were in opposite
114 M.I. Mahmoud et al.directions for the two outcomes. The Val allele was protective
for bronchial hyperresponsiveness, in agreement with the
results for asthma, but associated with increased risk of wheez-
ing. These effects were suggested by two relatively small studies,
but the large ALSPAC cohort did not provide convincing
evidence of any association with either outcome. Moreover,
the results from the ALSPAC, which represented the largest
sample in the meta-analysis, were negative. On the other hand,
GST genes could interact with genes coding for other detoxify-
ing enzymes which induced in response to oxidative stress. Sup-
porting this hypothesis is some evidence of interaction between
GSTM1 null genotype and NQO1 Pro187Ser polymorphism on
asthma.34
This systematic review8 only focused on asthma risk, and
did not consider the possible association of GST genes with
asthma severity in patients affected by the disease. A ﬁnding
from the Southampton study was the association of the
GSTT1 null allele with an increased severity score in patients
with asthma. There is evidence suggesting that GST genes, in
particular GSTM1 and GSTP1, might also interact with air
pollution and tobacco smoke exposures in exacerbating respi-
ratory symptoms and decreasing lung function in asthmatic
individuals.49,50
In contrast to our ﬁndings, Fryer et al.14 found that com-
pared with GSTP1 Ile105/Ile105, GSTP1 Val105/Val105 was
associated with a decreasing severity of bronchial hyperrespon-
siveness. The association between GSTP1 Val105/Val105 and
airway obstruction/reactivity remained signiﬁcant after correc-
tion for atopic status, age, and gender. Compared with GSTP1
Ile105/Ile105, the heterozygote genotype GSTP1 Ile105/Val105
was linked with a signiﬁcantly reduced risk of airway reactivity/
obstruction that was intermediate to that with the GSTP1
Ile105/Ile105 andGSTP1Val105/Val105 genotypes. These ﬁnd-
ings are compatible with their view that the association of
GSTP1 genotypes with clinical asthma phenotypes is predomi-
nantly with bronchial hyperresponsiveness. An underlying
cause for absence of association between airway dysfunction
and GSTP1 genotypes in our study may be the relatively small
number of patients with asthma.
Spiteri et al.6 found that trend analysis showed a signiﬁcant
decrease of GSTP1 Val/Val (with parallel increase of GSTP1
Ile/Ile) genotype frequency with increasing severity of airﬂow
obstruction/bronchial hyperresponsiveness.5. Conclusion
The present study does not support a substantial role of
GSTP1 gene polymorphism in the development of asthma.
Also, it is not related to the severity of asthma, degree of air-
way obstruction and/or atopy. However, large studies with
accurate measurement of the environmental exposure are
needed in order to reach adequate power to detect gene–envi-
ronment interactions and other genes involved in the antioxi-
dant pathway.References
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